According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda). The drug is one of the first checkpoint inhibitors to be developed and used in cancer treatment. The findings are published online today in the Journal of Clinical Oncology.
Study Shows Long-Term Survival Benefi... - Lung Conditions C...
Study Shows Long-Term Survival Benefit for Certain Patients with Advanced Lung Cancer.
Written by
2greys
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
I seem to be lurching from pillar to post, Oxygen compressors advice
tinnitus. A colon cancer repair all ok I hope, no scans because of covid .Skin cancer (waiting for...
Why I bought a Scooter
daily treatment for his mis-diagnosed prostate cancer he used it and said very convenient and easy....
Organising pneumonia - how soon do the steroids kick in?
the 2nd CT scan as a cancerous deposit on my rib. Looks like my breast cancer has come back. I see
My Bladder Cancer Update.
si no tumour growth.
I still have cancer cells because I have cancer in situ (CIS) but at moment...
update on hospital visit
was very much appreciated.
Good News! it’s not cancer, the consultant put sprays up my nose &...
Hurts breathing in on left side/lung...
Update on my health status
Ground glass opacity.
using a spacer for Spiriva 
Lung Cancer Treatment
